You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDecamethonium
Accession NumberDB01245  (APRD00696)
TypeSmall Molecule
GroupsApproved
DescriptionDecamethonium is a short acting depolarizing muscle relaxant or neuromuscular blocking agent, and is used in anesthesia to induce paralysis. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.
Structure
Thumb
Synonyms
Decamethonium
DECAMETHONIUM ion
Decamethonum
Decamethylenebis(trimethylammonium)
N,N,N,N',n',n'-hexamethyl-1,10-decanediaminium
External Identifiers
  • Lopac-D-1260
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SyncurineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Decamethonium bromide
ThumbNot applicableDBSALT001347
Categories
UNIIC1CG1S3T2W
CAS number156-74-1
WeightAverage: 258.4863
Monoisotopic: 258.303499226
Chemical FormulaC16H38N2
InChI KeyMTCUAOILFDZKCO-UHFFFAOYSA-N
InChI
InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
IUPAC Name
trimethyl[10-(trimethylazaniumyl)decyl]azanium
SMILES
C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
Pharmacology
IndicationFor use as a skeletal muscle relaxant
Structured Indications Not Available
PharmacodynamicsDecamethonium acts as a depolarizing muscle relaxant or neuromuscular blocking agent. It acts as an agonist of nicotinic acetycholine receptors in the motor endplate and causes depolarization. This class of drugs has its effect at the neuromuscular junction by preventing the effects of acetylcholine. Normally, when a nerve stimulus acts to contract a muscle, it releases acetylcholine. The binding of this acetylcholine to receptors causes the muscle to contract. Muscle relaxants play an important role in anesthesia even though they don't provide any pain relief or produce unconsciousness.
Mechanism of actionBinds to the nicotinic acetycholine receptors (by virtue of its similarity to acetylcholine) in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrance remains depolarized and unresponsive to any other impulse, causing muscle paralysis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Neuronal acetylcholine receptor subunit alpha-2Proteinyes
partial agonist
HumanQ15822 details
AcetylcholinesteraseProteinunknown
inhibitor
HumanP22303 details
Related Articles
AbsorptionRapidly absorbed.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=190 mg/kg (orally in mice). Prolonged apnoea, neuromuscular paralysis and cardiac arrest may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Decamethonium.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Decamethonium.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Decamethonium.Experimental, Illicit
AcebutololDecamethonium may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Acetylcholine.Approved
AcetyldigitoxinDecamethonium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AclarubicinAclarubicin may increase the respiratory depressant activities of Decamethonium.Investigational
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Decamethonium.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Decamethonium.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Decamethonium.Experimental
AlprenololDecamethonium may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Decamethonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Decamethonium.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Decamethonium.Approved
annamycinannamycin may increase the respiratory depressant activities of Decamethonium.Investigational
AnvirzelDecamethonium may increase the arrhythmogenic activities of Anvirzel.Investigational
Aop200704Decamethonium may increase the bradycardic activities of Aop200704.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Decamethonium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Decamethonium.Approved
ArecolineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Arecoline.Experimental
ArotinololDecamethonium may increase the bradycardic activities of Arotinolol.Approved
AtenololDecamethonium may increase the bradycardic activities of Atenolol.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Decamethonium.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Decamethonium.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Decamethonium.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decamethonium.Approved, Investigational
BefunololDecamethonium may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Decamethonium.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Decamethonium.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Decamethonium.Approved, Vet Approved
BetaxololDecamethonium may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Decamethonium is combined with Bethanechol.Approved
BevantololDecamethonium may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Decamethonium.Approved
BisoprololDecamethonium may increase the bradycardic activities of Bisoprolol.Approved
BopindololDecamethonium may increase the bradycardic activities of Bopindolol.Approved
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational
Botulinum Toxin Type BDecamethonium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BucindololDecamethonium may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Decamethonium.Approved
BufuralolDecamethonium may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
BupranololDecamethonium may increase the bradycardic activities of Bupranolol.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Decamethonium.Approved
CarbacholThe risk or severity of adverse effects can be increased when Decamethonium is combined with Carbachol.Approved
CarteololDecamethonium may increase the bradycardic activities of Carteolol.Approved
CarvedilolDecamethonium may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololDecamethonium may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Decamethonium.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Decamethonium.Approved, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Decamethonium.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decamethonium.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium.Approved
ColistimethateColistimethate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Decamethonium.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Decamethonium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational, Vet Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Decamethonium.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Decamethonium.Investigational
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Decamethonium.Approved
DeslanosideDecamethonium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Decamethonium.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Decamethonium.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Decamethonium.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Decamethonium.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decamethonium.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Decamethonium.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Decamethonium.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Decamethonium.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Decamethonium.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Decamethonium.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Decamethonium.Approved
DigitoxinDecamethonium may increase the arrhythmogenic activities of Digitoxin.Approved
DigoxinDecamethonium may increase the arrhythmogenic activities of Digoxin.Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Decamethonium.Vet Approved
DipyridamoleThe therapeutic efficacy of Decamethonium can be decreased when used in combination with Dipyridamole.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational, Vet Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Decamethonium is combined with EPIBATIDINE.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Decamethonium.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Decamethonium.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Decamethonium.Approved
EsmololDecamethonium may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Decamethonium.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Decamethonium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Decamethonium.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Decamethonium.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Decamethonium.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Decamethonium.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decamethonium.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Decamethonium.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Decamethonium.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Decamethonium.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Decamethonium.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Decamethonium.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Decamethonium.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Decamethonium.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Decamethonium.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Decamethonium.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Decamethonium.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Decamethonium.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Decamethonium.Approved, Investigational, Withdrawn
FramycetinFramycetin may increase the respiratory depressant activities of Decamethonium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Decamethonium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Decamethonium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Decamethonium.Experimental
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Decamethonium.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Decamethonium is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Decamethonium.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Decamethonium.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Decamethonium.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decamethonium.Approved, Vet Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Decamethonium.Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Decamethonium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Decamethonium.Approved
IndenololDecamethonium may increase the bradycardic activities of Indenolol.Withdrawn
INNO-206INNO-206 may increase the respiratory depressant activities of Decamethonium.Investigational
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Decamethonium.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Decamethonium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
LabetalolDecamethonium may increase the bradycardic activities of Labetalol.Approved
LevobunololDecamethonium may increase the bradycardic activities of Levobunolol.Approved
LithiumLithium may increase the neuromuscular blocking activities of Decamethonium.Approved
LobelineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Lobeline.Investigational
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Decamethonium.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Decamethonium.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Decamethonium.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Decamethonium.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Decamethonium.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium.Approved, Vet Approved
MetipranololDecamethonium may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Decamethonium.Approved
MetoprololDecamethonium may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetrizamideMetrizamide may increase the respiratory depressant activities of Decamethonium.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational
MivacuriumDecamethonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Decamethonium.Vet Approved
NadololDecamethonium may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Decamethonium.Investigational
NeamineNeamine may increase the respiratory depressant activities of Decamethonium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Decamethonium.Approved
NicotineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Decamethonium is combined with Nicotine bitartrate.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Decamethonium.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Decamethonium.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Decamethonium.Approved
OuabainDecamethonium may increase the arrhythmogenic activities of Ouabain.Approved
OxprenololDecamethonium may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Decamethonium.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Decamethonium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Decamethonium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Decamethonium.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
PenbutololDecamethonium may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Decamethonium.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Pilocarpine.Approved
PindololDecamethonium may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Decamethonium.Investigational
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Decamethonium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Decamethonium.Experimental
PlicamycinPlicamycin may increase the respiratory depressant activities of Decamethonium.Approved, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
PractololDecamethonium may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Decamethonium.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Decamethonium.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Decamethonium.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Decamethonium.Experimental
ProcainamideProcainamide may increase the neuromuscular blocking activities of Decamethonium.Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Decamethonium.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Decamethonium.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Decamethonium.Investigational
PropranololDecamethonium may increase the bradycardic activities of Propranolol.Approved, Investigational
PuromycinPuromycin may increase the respiratory depressant activities of Decamethonium.Experimental
QuinidineQuinidine may increase the neuromuscular blocking activities of Decamethonium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Decamethonium.Approved
RapacuroniumDecamethonium may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RibostamycinRibostamycin may increase the respiratory depressant activities of Decamethonium.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Decamethonium.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Decamethonium.Approved
SisomicinSisomicin may increase the respiratory depressant activities of Decamethonium.Investigational
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Decamethonium.Approved
SotalolDecamethonium may increase the bradycardic activities of Sotalol.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Decamethonium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Decamethonium.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Decamethonium.Approved
TetracyclineTetracycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
TimololDecamethonium may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Decamethonium.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Decamethonium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Decamethonium.Approved, Investigational
TorasemideTorasemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Decamethonium.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Decamethonium.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Decamethonium.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Decamethonium.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Decamethonium.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Decamethonium.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Decamethonium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Decamethonium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Decamethonium.Approved
VareniclineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Decamethonium.Approved
ZorubicinZorubicin may increase the respiratory depressant activities of Decamethonium.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (56.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9862
Blood Brain Barrier+0.9444
Caco-2 permeable+0.7036
P-glycoprotein substrateSubstrate0.5439
P-glycoprotein inhibitor INon-inhibitor0.9679
P-glycoprotein inhibitor IINon-inhibitor0.7809
Renal organic cation transporterNon-inhibitor0.5386
CYP450 2C9 substrateNon-substrate0.8398
CYP450 2D6 substrateNon-substrate0.661
CYP450 3A4 substrateNon-substrate0.5423
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9607
CYP450 2D6 inhibitorNon-inhibitor0.9633
CYP450 2C19 inhibitorNon-inhibitor0.9288
CYP450 3A4 inhibitorNon-inhibitor0.9882
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9899
Ames testNon AMES toxic0.9423
CarcinogenicityCarcinogens 0.6778
BiodegradationNot ready biodegradable0.5263
Rat acute toxicity2.6822 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7991
hERG inhibition (predictor II)Non-inhibitor0.6249
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point268-270 °CNot Available
water solubilitySubstantialNot Available
Predicted Properties
PropertyValueSource
Water Solubility7.04e-06 mg/mLALOGPS
logP-2.8ALOGPS
logP-4.9ChemAxon
logS-7.7ALOGPS
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity106.95 m3·mol-1ChemAxon
Polarizability35.94 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as decamethonium compounds. These are quaternary ammonium compounds containing a trimethyl-(10-trimethylammoniodecyl)ammonium moiety.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassQuaternary ammonium salts
Sub ClassDecamethonium compounds
Direct ParentDecamethonium compounds
Alternative Parents
Substituents
  • Decamethonium
  • Hydrocarbon derivative
  • Amine
  • Organic cation
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Lee C, Jones T: Molecular conformation-activity relationship of decamethonium congeners. Br J Anaesth. 2002 May;88(5):692-9. [PubMed:12067008 ]
  4. Maneckjee R, Minna JD: Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40. [PubMed:7848904 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Robaire B, Kato G: Effects of edrophonium, eserine, decamethonium, d-tubocurarine, and gallamine on the kinetics of membrane-bound and solubilized eel acetylcholinesterase. Mol Pharmacol. 1975 Nov;11(6):722-34. [PubMed:1207670 ]
  2. Sinha BK, Chignell CF: Synthesis and biological activity of spin-labeled analogs of biotin, hexamethonium, decamethonium, dichlorisoproterenol, and propranolol. J Med Chem. 1975 Jul;18(7):669-73. [PubMed:239236 ]
  3. Wu CS, Yang JT: Tacrine protection of acetylcholinesterase from inactivation by diisopropylfluorophosphate: a circular dichroism study. Mol Pharmacol. 1989 Jan;35(1):85-92. [PubMed:2913485 ]
  4. Seto Y, Shinohara T: Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch Toxicol. 1988 Aug;62(1):37-40. [PubMed:3190453 ]
  5. Hallek M, Szinicz L: Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro. Biochem Pharmacol. 1988 Mar 1;37(5):819-25. [PubMed:3345199 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Munoz-Delgado E, Vidal CJ: Kinetic behaviour of acetylcholinesterase from muscle microsomal membranes. Biochem Int. 1986 Oct;13(4):625-32. [PubMed:3801037 ]
  2. Danilov AF: [Inhibition of cholinesterase in the myoneural synapses by decamethonium and ditilin]. Farmakol Toksikol. 1967 Nov-Dec;30(6):664-9. [PubMed:5598433 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23